An observational study in Bladder Cancer and Urothelial Carcinoma, sponsored by Zhongnan Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-09.
Sponsored by Zhongnan Hospital · Observational
Bladder cancer is the second most prevalent urological malignancy worldwide, with a high incidence and poor patient prognosis. Achieving early diagnosis and intervention for bladder cancer is one of the most important ways to improve clinical management and patient prognosis. Tumor exosomes can be released into biological fluids at an early stage of a tumor, and many studies have shown that exosomal RNA can be used as a reliable biomarker to diagnose tumors in a non-invasive way. Based on the clinical needs for early diagnosis of bladder cancer, we aim to screen several early diagnostic markers with potential predictive value, establish an early diagnostic model for bladder cancer, and validate the validity and reliability of this diagnostic model through a large-scale clinical cohort to complement the diagnosis of early-stage cancers and to improve the rate of early diagnosis of cancer.
In response to the clinical demand for accurate early diagnosis of bladder cancer, this project aims to gradually conduct in-depth research on precise early diagnosis of bladder cancer. This includes establishing key techniques for efficient and convenient enrichment of exosomes, identifying potential exosome biomarkers for bladder cancer based on bladder cancer transcriptome sequencing data, and conducting large-scale clinical cohort studies.
143 studies on the registry are indexed under Urologic Neoplasms; 42 are open to participants now.
This study's enrollment of 400 is above the median of 200 across 33 observational studies indexed under Urologic Neoplasms.
Browse Urologic Neoplasms studies →Zhongnan Hospital is the lead sponsor of 103 studies on the registry; 48 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with bladder cancer treated in Zhongnan Hospital of Wuhan University
Exclusion Criteria:
Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
Diagnostic Test: RT-qPCR
Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
Diagnostic Test: RT-qPCR
Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
Diagnostic Test: RT-qPCR
RT-qPCR
RT-qPCR
Urine exosomal RNA
Time frame: Urine exosomes were enriched for RT-qPCR within 4 hours after the samples were collected.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhongnan Hospital